

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/004875

International filing date: 10 February 2005 (10.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/608,522  
Filing date: 08 September 2004 (08.09.2004)

Date of receipt at the International Bureau: 17 March 2005 (17.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1294250

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*March 09, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/608,522**

**FILING DATE: *September 08, 2004***

**RELATED PCT APPLICATION NUMBER: *PCT/US05/04875***



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

17698 U.S. PTO  
090804

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0851-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV 319441440 US

19249 U.S. PTO  
60/608522

090804

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Quanlai		Song		Encinitas, CA	
Additional inventors are being named on the <u>1</u> separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
MONOMERS FOR IMPROVED RNA AND DNA SOLUTION PHASE SYNTHESIS					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number: <div style="border: 1px solid black; padding: 5px; display: inline-block;">27180</div>					
OR					
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		Zip	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages <u>2</u>					
<input type="checkbox"/> Drawing(s) Number of Sheets _____					
<input type="checkbox"/> Application Date Sheet. See 37 CFR 1.76					
<input type="checkbox"/> CD(s), Number _____					
<input type="checkbox"/> Other (specify) _____					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.					
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <u>500252</u>					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
FILING FEE Amount (\$) <div style="border: 1px solid black; padding: 10px; display: inline-block;">160.00</div>					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

[Page 1 of 2]

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME

TELEPHONE

Herb Boswell

760-603-2385

Date September 8, 2004

REGISTRATION NO.

(if appropriate)

Docket Number: DVCM0021US.L

27,311

**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**PROVISIONAL APPLICATION COVER SHEET**  
**Additional Page**

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number DVC M0021US.L

[illegible]

[Page 2 of 2]

Number 2 of 2


**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

4. DESCRIPTION OF INVENTION: (Pinpoint novel features: If new chemical compound - formula of generic concept, sample preparation from known starting materials. If new pharmaceutical composition or use - ingredients, dose regimens and preparation. If machine or chemical process - critical components and operation. Attach additional signed and dated pages or diagrams as necessary; indicate number of pages attached \_\_\_\_):\_

As we have previously demonstrated, a convergent, solution phase synthesis of DNA via 3-6mer blocks of 5'-O-DMT protected H-phosphonate monomers is likely to be the most efficient and scalable method to produce commercial quantities of therapeutic oligonucleotides. This method can be further improved by combining our previously disclosed 5' protecting group, the substituted pixyl. This new combination could be used in a further combination with various 2'-substitutions such as 2'-deoxy, 2'-O-alkyl (eg 2-methoxyethyl), 2'-deoxy-2'-halo (eg fluoro), 2'-protected hydroxyl (eg Cpep or tBDMS).

The use of substituted pixyl nucleoside derivatives over dimethoxytrityl (DMT) ones allow for certain advantages:


1. We have observed that pixyl derivatives are far easier to crystallize than the analogous DMT derivatives. Currently, each DMT derivative from monomer to each length of blockmer must be purified by silica gel chromatography. This limits the scale, increases the expense and potentially introduces newly generated degradation impurities. Purification by crystallization is usually superior, especially at production scale.
2. We can choose the substituted pixyl with the optimum acid stability for the base and sugar components in use. Both the pixyls and DMT are removed with acid. During this treatment, the rest of the oligonucleotide is vulnerable to degradation. The amount of degradation is dependent upon the acid strength and/or the exposure time. Notably deoxyadenosine and deoxyguanosine will depurinate and acid sensitive RNA protecting groups such as Cpep will also degrade if there are any traces of water present. Furthermore, solution phase chemistry requires longer acid exposure time than solid phase synthesis. More acid sensitive pixyls will allow for less acid exposure and therefore allow less acid caused degradation.
3. Pixyl cations are known to be scavenged more efficiently than the DMT cation. As noted above, solution phase synthesis requires longer exposure to acidic deprotection conditions. The cation of the 5'-protecting group is in the same solution as the freed 5'-hydroxyl and is not washed away continuously as in the solid phase method. To minimize the reverse reaction, the cation can be scavenged and trapped with another nucleophile that can outcompete the 5'-hydroxyl. Reese has shown that adding pyrrole or triethylsilane efficiently traps pixyl cations and thus allows for even less exposure to acid.



Where B = A, C, G, U and their derivatives  
and R = H, F, O-Me, O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, O-Cpep, O-Fmp,  
O-tBDMS, etc  
and sub-Px = DMPx, etc

### Example 1

Triethylammonium 5'-O-DMPx-thymidine 3'-H-phosphonate



Ammonium phenyl H-phosphonate (5.25g, 30 mmol), 5'-O-DMPx-thymidine (5.4 g, 10 mmol) and triethylamine (8.4 ml, 60 mmol) in pyridine (50 ml) were evaporated together under reduced pressure. The residue was coevaporated with dry pyridine (50 ml). The residue was dissolved in dry pyridine (50 ml) and the solution was cooled to 0°C. Pivaloyl chloride (3.7 ml, 30 mmol) was added dropwise over 10 min. After 30 min at 0°C, water (10 ml) was added and the stirred mixture was allowed to warm up to room temperature. Potassium phosphate buffer (1.0 M, pH 7.0, 250 ml) was added and the resulting mixture was concentrated under reduced pressure until all pyridine was removed. The residue was partitioned between dichloromethane (250 ml) and water (200ml). The organic layer was washed with triethylammonium phosphate buffer (0.5 M, pH 7, 3x100ml) and then evaporated. The residue was purified by a short silica gel column, eluted with dichloromethane-methanol (95:5 to 90:10). Evaporation of appropriate fractions to give the desired product (7.1 g).

5. UTILITY: (Describe the usefulness of the invention.)

The invention will allow us to produce DNA, DNA-substituted RNA hybrid, RNA, RNA-substituted RNA hybrid oligonucleotides for antisense, RNAi, miRNA applications on a commercial scale in a more efficient process and with higher purity.

6. WORKABLE EXTENT: (Describe plans for future work and envisaged variations of the invention.)

Future work first includes the synthesis of all our commonly used 2'-substituents (deoxy, methoxyethyl, methyl, fluoro, Cpep protected hydroxyl) as substituted pixyl H-phosphonate monomers. The monomers will be assembled into blocks and finally oligonucleotides of current interest in research and development.

7. REFERENCES: List particularly relevant references, including patents and publications  
(To be done later)

Previous provisional application for substituted pixyls

Reese publication on blockmer synthesis, unpublished internal report on our blockmer synthesis

Reese publication on pixyls

8. COLLABORATION, SUPPORT:

Is there any corporate collaboration? ☐ Yes ☒ ☒ No If yes, name? \_\_\_\_\_

Is this research supported by a gov't grant (SBIR, etc.)? ☐ Yes ☒ ☒ No Grant number \_\_\_\_\_